Discovery of a potent inhibitor of the antiapoptotic protein Bcl-X L from NMR and parallel synthesis

Andrew M. Petros, Jurgen Dinges, David J. Augeri, Steven A. Baumeister, David A. Betebenner, Mark G. Bures, Steven W. Elmore, Philip J. Hajduk, Mary K. Joseph, Shelley K. Landis, David G. Nettesheim, Saul H. Rosenberg, Wang Shen, Sheela Thomas, Xilu Wang, Irini Zanze, Haichao Zhang, Stephen W. Fesik

Research output: Contribution to journalArticlepeer-review

252 Scopus citations

Abstract

The antiapoptotic proteins Bcl-xL and Bcl-2 play key roles in the maintenance of normal cellular homeostasis. However, their overexpression can lead to oncogenic transformation and is responsible for drug resistance in certain types of cancer. This makes Bcl-xL, and Bcl-2 attractive targets for the development of potential anticancer agents, Here we describe the structure-based discovery of a potent Bcl-xL inhibitor directed at a hydrophobic groove on the surface of the protein. This groove represents the binding site for BH3 peptides from proapoptotic Bcl-2 family members such as Bak and Bad. Application of NMR-based screening yielded an initial biaryl acid with an affinity (Kd) of ∼300 μM for the protein. Following the classical "SAR by NMR" approach, a second-site ligand was identified that bound proximal to the first-site ligand in the hydrophobic groove. From NMR-based structural studies and parallel synthesis, a potent ligand was obtained, which binds to Bcl-xL with an inhibition constant (K i) of 36 ± 2 nM.

Original languageEnglish (US)
Pages (from-to)656-663
Number of pages8
JournalJournal of Medicinal Chemistry
Volume49
Issue number2
DOIs
StatePublished - Jan 26 2006
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Drug Discovery
  • Molecular Medicine

Fingerprint

Dive into the research topics of 'Discovery of a potent inhibitor of the antiapoptotic protein Bcl-X <sub>L</sub> from NMR and parallel synthesis'. Together they form a unique fingerprint.

Cite this